Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL)

被引:22
|
作者
Braess, J
Reich, K
Willert, S
Strutz, F
Neumann, C
Hiddemann, W
Wörmann, B
机构
[1] Univ Gottingen, Klinikum Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany
[2] Klinikum Gottingen, Dept Nephrol, Gottingen, Germany
[3] Klinikum Gottingen, Dept Dermatol, Gottingen, Germany
关键词
fludarabine; autoimmune side effects; lymphoma; T cell; pemphigus;
D O I
10.1007/s002770050347
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 40-year-old patient with low-grade B-NHL developed a generalized macular-papular rash following the first cycle of fludarabine treatment which progressed to a complete epidermal necrolysis following the second cycle. Clinical symptoms and the results of the direct and indirect immunofluorescence were consistent with a mucocutaneous autoimmune syndrome (pemphigus). Immunohistochemical analysis demonstrated a dense epidermal infiltration of CD8+ lymphocytes associated with the histological features of single-cell necrosis of keratinocytes. Early and aggressive immunosuppressive treatment with steroids, cyclophosphamide, and high-dose immunoglobulins resulted in regression of symptoms and complete reconstitution of epidermal integrity. The malignant lymphoma has completely regressed. The findings suggest a fludarabine-induced defect in immunosurveillance - resulting in the uncontrolled activation of autoaggressive T-cell clones - as a pathogenetic mechanism of this life-threatening dermatological complication.
引用
收藏
页码:227 / 230
页数:4
相关论文
共 50 条
  • [41] THE PROFILING OF CIRCULATING TUMOR DNA IN PEDIATRIC MATURE B-CELL NON-HODGKIN LYMPHOMA (B-NHL): A MULTICENTER, PROSPECTIVE CLINICAL STUDY
    Wang, J.
    Guo, H.
    Cai, Y.
    Chen, H.
    Yang, L.
    Dou, H.
    Tian, X.
    Xiong, H.
    Hong, X.
    Liang, C.
    Zhen, Z.
    Zhu, J.
    Lu, S.
    Sun, F.
    Huang, J.
    Zhang, Y.
    LEUKEMIA RESEARCH, 2022, 121 : S30 - S32
  • [42] The Profiling of Circulating Tumor DNA in Pediatric Mature B-Cell Non-Hodgkin Lymphoma(B-NHL): A Multicenter, Prospective Clinical Study
    Wang, J.
    Yun, C.
    Huiqin, C.
    Liangchun, Y.
    Guo, H.
    Huihong, D.
    Xin, T.
    Xiaoyu, H.
    Chuqiao, L.
    Zhen, Z.
    Zhu, S.
    Lu, S.
    Sun, F.
    Huang, J.
    Zhang, Y.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S79 - S79
  • [43] Biallelic inactivation of TP53 is associated with an increased risk of relapse in paediatric B-cell Non-Hodgkin lymphoma (B-NHL)
    Newman, Alexander M.
    Zaka, Masood
    Zhou, Peixun
    Erhorn, Amy
    Barnard, Amy
    Crossland, Rachel E.
    Wilkinson, Sarah
    Enshaei, Amir
    Taj, Mary
    Wood, Katrina
    Televantou, Despina
    Turner, Suzanne D.
    Burke, Amos
    Harrison, Christine J.
    Bomken, Simon
    Bacon, Chris M.
    Rand, Vikki
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 60 - 60
  • [44] Biallelic Inactivation of TP53 is Associated with an Increased Risk of Relapse in Paediatric B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Newman, A. M.
    Zaka, M.
    Zhou, P.
    Erhorn, A.
    Barnard, A.
    Crossland, R. E.
    Wilkinson, S.
    Wood, K.
    Televantou, D.
    Harrison, C. J.
    Bomken, S.
    Bacon, C. M.
    Rand, V.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S46 - S47
  • [45] Dosimetry results of Oncolym™ in the treatment of refractory B-cell non-Hodgkin's lymphoma (NHL).
    Verkh, LI
    Murray, JL
    Kripas, CJ
    Wessels, BW
    Varma, VM
    Kahn, D
    Bushnell, DL
    Serafini, AN
    Oliver, JC
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1998, 13 (01) : 66 - 66
  • [46] Reduced Burden of Therapy in Intermediate Risk Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): Preliminary Results of the Reduced Burden of Oncologic Therapy (REBOOT) Trial
    Barth, M. J.
    Goldman, S. C.
    Oesterheld, J.
    Heym, K.
    Harrison, L.
    Nickerson, B.
    Cairo, M. S.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S36 - S36
  • [47] New drugs for B-cell non-Hodgkin's lymphomas (NHL)
    Cheson, B. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 127 - 127
  • [48] Fludarabine (FLU) in combination: An effective therapy for relapsed or refractory low-grade non-Hodgkin's lymphoma (LGL)
    Santini, G
    Nati, S
    Spriano, M
    Congiu, AM
    Marino, G
    Rossi, E
    Vimercati, R
    Pierluigi, D
    Clavio, M
    Gobbi, M
    Damasio, E
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 80 - 80
  • [49] Outcome of relapsed childhood B-cell acute lymphoblastic leukaemia (B-ALL) and B-cell non-Hodgkin's lymphoma (B-NHL) treated with UKCCSG 9003/9002 protocols.
    Atra, A
    Hobson, R
    Imeson, JD
    Gerrard, M
    Pinkerton, CR
    BLOOD, 1998, 92 (10) : 233B - 233B
  • [50] Phase II trial of fludarabine alternating with interferon (IFN)alpha 2B in low grade non-Hodgkin's lymphoma (NHL)
    Smith, MR
    Boyd, RL
    Minnitti, C
    Clyde, J
    Hoessly, MC
    Cornfeld, M
    Yeslow, G
    Halbherr, T
    Rogatko, A
    Schilder, RJ
    Young, RC
    Millenson, MM
    BLOOD, 1997, 90 (10) : 861 - 861